Navigation Links
RPS Continues Expansion of Global Clinical, Regulatory, Medical, and Operational Leadership
Date:7/20/2011

FORT WASHINGTON, Pa., July 20, 2011 /PRNewswire/ -- ReSearch Pharmaceutical Services, Inc. (RPS), a next generation CRO that provides comprehensive global Phase II-IV clinical development solutions to the biopharmaceutical and medical device industries, today announced the following key additions to its Operational and Senior Management team.  

  • John K. Davis, II, as Chief Information Officer and Executive Vice President, Clinical Systems
  • Martine Dehlinger-Kremer, Ph.D. as Vice President, Global Regulatory Affairs
  • Debra Marshall as Vice President, Clinical Programs and Global Site Management
  • Lexy Kelley, MD as Medical Director, Immunology Development Services
  • Peggy Doran as Executive Director, R&D Business Operations Management

"RPS is extremely pleased to add such a talented and experienced team to our organization," said Harris Koffer, Pharm.D., President and COO.  "These additions will further strengthen our position as an innovator and leading provider of Embedded and Full-Service clinical development solutions in support of our clients expanding global product development needs."

John K. Davis, II brings more than 30 years of experience as an accomplished CIO and operations executive.  He previously served as Senior Vice President and Chief Information Officer at the American Board of Internal Medicine (ABIM) and Executive Vice President and CIO at Omnicare Clinical Research, where he led the globalization of the Clinical Data Management, Biostatistics, Information Technology, Clinical Writing, and Training functions.  

Martine Dehlinger-Kremer, Ph.D. has over 24 years of experience in the pharmaceutical industry with extensive expertise in global Regulatory Affairs.  She most recently served as the Vice President of Global Regulatory Affairs and Global Medical Affairs at Theorem Clinical Research (previously Omnicare Clinical Research). 

Debra Marshall has over 30 years of healthcare and pharmaceutical industry management experience and most recent served as Assistant Vice President, US Global Site Management for Pfizer (formerly Wyeth), where she was instrumental in building a high performing Site Management Organization and implementing enhanced Site Management strategies.

Lexy Kelley, MD brings strong experience in the design, implementation and medical oversight of clinical development programs for the treatment of Lupus as well as clinical research experience in hematology, infectious diseases, rheumatology and allergy.  Prior to joining RPS, she served as an Associate Medical Director at UCB Pharma.

Marguerite (Peggy) Doran has over 25 years of pharmaceutical industry experience, including 18 years of experience in contract negotiation and management, implementation of sourcing strategies, contract optimization and process improvements as well as vendor relationship management and governance programs.

"Because of our unique business model, RPS has achieved impressive growth rates that far exceed those in the late stage CRO marketplace," said Daniel M. Perlman, Chairman and CEO.  "The new additions to our organization are a key component of our continued focus on growth and innovation in support of the global biopharmaceutical and medical device industries."

About RPS

RPS provides comprehensive global Phase II-IV clinical development solutions to the Pharmaceutical, Biotechnology, Medical Device and Diagnostic industries.  By combining our highly experienced clinical research operations infrastructure with the industry's largest resourcing engines, RPS is uniquely positioned to offer our Customers a broad spectrum of outsourcing solutions. These solutions range from globally Embedded functional and cross-functional programs to enhanced global full-service solutions, and are powered by highly experienced project teams providing innovative, seamless, cost-effective and high quality services.

With more than 3,000 employees, RPS operates in 45 countries across the globe.


'/>"/>
SOURCE ReSearch Pharmaceutical Services, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Beardsworth Continues to Strengthen Oncology Operations
2. SeqWright Continues Expansion of Next-Generation Sequencing Capabilities
3. Fourth Annual Probiotics Grant Continues to Fuel Growth In Research
4. IGEN Networks Corp continues to build a world class advisory board, with the appointment of three new members
5. Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation
6. New Test Centre in India: TUV Rheinland Continues Worldwide Investment Programme for Solar Industry
7. Simbionix Continues its Global Expansion
8. O2h Continues to Support Senexis to Support Patent Filing Senexis Limited
9. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
10. NEVO(TM) Sirolimus-Eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve-Month Data
11. Dehaier Medical Systems Continues Product Line Expansion. Signs Exclusive Distribution Agreement with HEYER Medical for Respiratory Products in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... N.J. , Dec. 8, 2016 Soligenix, ... biopharmaceutical company focused on developing and commercializing products to ... need, announced today that it will be hosting an ... am ET on the origins of innate defense regulators ... a review of oral mucositis and the recently announced ...
(Date:12/8/2016)... Savannah River Remediation LLC group evaluated ... NT-MAX Lake & Pond Sludge and Muck ... conjunction with Hexa Armor/ Rhombo cover manufactured by ... Discharge Elimination System requirements. The Savannah ... of elevated pH levels, above 8.5, especially during ...
(Date:12/8/2016)... Dec. 8, 2016  Partnering to fuel ... Technology Partners of Southeastern Pennsylvania ... parent company of Independence Blue Cross; and Safeguard Scientifics ... intentions for a $6 million funding initiative over a ... Responding to a burgeoning economic vitality in ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... its phase I/II dose escalation and expansion clinical trial for its lead drug ... Austria. The purpose of the trial was to determine the safety, antitumor activity, ...
Breaking Biology Technology:
(Date:12/5/2016)... WASHINGTON , Dec. 5, 2016  The ... (NIJ), today published "Can CT Scans Enhance or ... examines the potential of supporting or replacing forensic ... a CT scan. In response to ... NIJ is exploring using CT scans as a ...
(Date:11/30/2016)... Nov. 30, 2016  higi SH llc (higi) ... initiative targeting national brands, industry thought-leaders and celebrity ... respective audiences for taking steps to live healthier, ... in 2012, higi has built the largest self-screening ... 38 million people who have conducted over 185 ...
(Date:11/28/2016)... Nov. 28, 2016 "The ... of 16.79%" The biometric system market is in ... in the near future. The biometric system market is ... 2022, at a CAGR of 16.79% between 2016 and ... of biometric technology in smartphones, rising use of biometric ...
Breaking Biology News(10 mins):